Triple-Negative Breast Cancer (TNBC) Treatment in Shanghai: A Guide for International Patients
Triple-negative breast cancer (TNBC) is defined by the absence of three receptors that drive most breast cancers: estrogen receptor (ER), progesterone receptor (PR), and HER2. This absence means that hormone therapies and HER2-targeted drugs — which have transformed outcomes for other breast cancer subtypes — are not effective for TNBC. For decades, chemotherapy was the only systemic option.
That landscape has changed dramatically. The approval of immunotherapy (pembrolizumab) in combination with chemotherapy for early-stage and metastatic TNBC, the emergence of PARP inhibitors for BRCA-mutated TNBC, and the development of antibody-drug conjugates (ADCs) such as sacituzumab govitecan have created a new era of treatment options. Shanghai's leading breast oncology centers — particularly Fudan University Shanghai Cancer Center (FUSCC) — are at the forefront of implementing and researching these advances for Chinese and international patients alike.
Understanding TNBC: Key Biological Features
TNBC accounts for approximately 15–20% of all breast cancers but is responsible for a disproportionate share of breast cancer mortality due to its aggressive behavior and limited targeted treatment options. Several biological features are clinically important:
PD-L1 Expression: The most important biomarker for immunotherapy eligibility in TNBC. Pembrolizumab (Keytruda) is approved in combination with chemotherapy for PD-L1-positive (CPS ≥10) metastatic TNBC and for early-stage TNBC regardless of PD-L1 status. PD-L1 testing should be performed on all newly diagnosed TNBC patients.
BRCA1/2 Mutation Status: Germline BRCA1 and BRCA2 mutations are significantly more common in TNBC than in other breast cancer subtypes. BRCA-mutated TNBC is eligible for PARP inhibitor therapy (olaparib, niraparib) and may have distinct chemotherapy sensitivity profiles. Genetic testing is recommended for all TNBC patients.
TROP-2 Expression: The target of sacituzumab govitecan (Trodelvy), an antibody-drug conjugate approved for metastatic TNBC after two prior lines of therapy. TROP-2 is broadly expressed in TNBC, making most patients potentially eligible.
Tumor Mutational Burden (TMB) & Microsatellite Instability (MSI): High TMB or MSI-H status may predict response to immunotherapy in patients who do not meet PD-L1 criteria. These biomarkers should be assessed as part of comprehensive molecular profiling.
Androgen Receptor (AR) Expression: A subset of TNBC tumors (approximately 10–15%) express the androgen receptor, defining a LAR (luminal androgen receptor) subtype that may respond to anti-androgen therapy. AR testing is increasingly incorporated into TNBC workup at specialized centers.
TNBC Subtypes: The FUSCC Classification
Researchers at Fudan University Shanghai Cancer Center have made a globally recognized contribution to TNBC biology: the development of a four-subtype molecular classification system for TNBC, published in leading international journals. This classification — identifying BL1, BL2, M, and LAR subtypes — has informed subtype-specific treatment strategies and clinical trial design. For international patients consulting at FUSCC, this molecular subtyping framework may be applied to guide treatment decisions beyond standard biomarker testing.
Treatment by Disease Stage
Early-Stage TNBC (Stages I–III)
Neoadjuvant chemotherapy + immunotherapy: The current standard for most early-stage TNBC patients is neoadjuvant (pre-surgical) chemotherapy. The KEYNOTE-522 trial established that adding pembrolizumab to neoadjuvant chemotherapy significantly improves pathological complete response (pCR) rates and event-free survival, regardless of PD-L1 status. Patients who achieve pCR at surgery have substantially better long-term outcomes.
Surgery: Breast-conserving surgery (lumpectomy) or mastectomy, with sentinel lymph node biopsy or axillary dissection as indicated. Plastic surgery reconstruction options are available at leading Shanghai centers for patients undergoing mastectomy.
Adjuvant therapy: Patients who do not achieve pCR after neoadjuvant chemotherapy are candidates for adjuvant capecitabine, which has been shown to improve disease-free survival in this setting. Adjuvant pembrolizumab (continuing from neoadjuvant) is also standard for eligible patients. For BRCA-mutated patients, adjuvant olaparib is an option.
Radiation therapy: Indicated after breast-conserving surgery and in selected mastectomy patients with nodal involvement.
Metastatic TNBC (Stage IV)
Metastatic TNBC remains one of the most challenging oncological situations, with median survival of approximately 12–18 months in unselected populations. However, the treatment landscape has improved significantly:
First-line: Pembrolizumab + chemotherapy (PD-L1 CPS ≥10): For PD-L1-positive metastatic TNBC, pembrolizumab combined with chemotherapy (nab-paclitaxel, paclitaxel, or gemcitabine/carboplatin) is the standard first-line approach, based on the KEYNOTE-355 trial.
PARP inhibitors (BRCA-mutated): Olaparib and niraparib are approved for germline BRCA-mutated HER2-negative metastatic breast cancer, including TNBC. These oral agents offer a chemotherapy-free option with meaningful response rates in this molecularly selected population.
Sacituzumab govitecan (Trodelvy): An ADC approved for metastatic TNBC after two or more prior lines of therapy. Response rates of approximately 35% and improved overall survival versus chemotherapy have been demonstrated in the ASCENT trial. Availability in China has been expanding through import and clinical trial access.
Subsequent chemotherapy lines: Capecitabine, eribulin, vinorelbine, and platinum-based regimens remain options for later-line treatment.
Clinical trials: Given the active research landscape in TNBC, clinical trial participation should be considered at every line of therapy. Shanghai's leading centers have ongoing trials in novel ADCs, bispecific antibodies, cell therapy, and combination immunotherapy strategies.
Leading Shanghai Specialists for TNBC
Fudan University Shanghai Cancer Center (FUSCC)
FUSCC is China's premier dedicated cancer center and the national leader in breast cancer research and treatment. Its breast oncology program is internationally recognized, with faculty publishing in Nature Medicine, Cancer Cell, Journal of Clinical Oncology, and other top-tier journals. For TNBC specifically, FUSCC's molecular subtyping research and clinical trial portfolio make it the most important center in China for this disease.
CMCS works with leading FUSCC breast oncologists including:
- Prof. Zhang Jian (张剑) — medical oncologist specializing in breast cancer systemic therapy and clinical research
- Prof. Wang Biyun (王碧詠) — expert in metastatic breast cancer and novel therapeutic strategies
- Dr. Wang Jialei (王佳蔓) — medical oncologist with expertise in breast and lung cancer
- Prof. Wu Jiong (吴炵) — Chief of Breast Surgery, expert in breast-conserving surgery and oncoplastic techniques
Ruijin Hospital — Shanghai Jiao Tong University
Ruijin Hospital's breast surgery program, led by Prof. Shen Kunwei (沈坤炮), is one of Shanghai's most respected outside of FUSCC. Ruijin offers strong surgical expertise combined with access to medical oncology and radiation oncology for comprehensive TNBC management.
Huashan Hospital — Fudan University
Dr. Zhuang Rongyuan (庄荣源) at Huashan Hospital provides medical oncology expertise for breast cancer patients, including TNBC, within the broader Fudan University medical ecosystem.
Breast Reconstruction After Mastectomy
For TNBC patients undergoing mastectomy, breast reconstruction is an important quality-of-life consideration. Shanghai's leading centers offer immediate and delayed reconstruction options including implant-based reconstruction, autologous tissue flaps (DIEP, TRAM, latissimus dorsi), and oncoplastic techniques for breast-conserving surgery. CMCS works with Dr. Liu Chunmei (刘春梅), a plastic surgeon specializing in post-cancer breast reconstruction.
Genetic Counseling and BRCA Testing
All TNBC patients should undergo germline genetic testing for BRCA1/2 mutations, as well as consideration of broader hereditary cancer panel testing. A positive BRCA result has implications not only for treatment selection (PARP inhibitor eligibility) but also for surgical decision-making (contralateral prophylactic mastectomy) and family members' cancer risk. CMCS can coordinate genetic counseling and testing as part of the initial consultation process.
What to Prepare Before Your Shanghai Consultation
- Pathology report confirming ER/PR/HER2 negativity, Ki-67 proliferation index, and histological grade
- PD-L1 testing result (CPS score using 22C3 assay) if already performed
- BRCA1/2 germline testing result if already performed
- Comprehensive molecular profiling (NGS panel) if available
- Staging imaging: CT chest/abdomen/pelvis, bone scan or PET-CT
- Prior treatment records: chemotherapy regimens, cycles, response assessments
- Surgical records if prior surgery has been performed
- Radiation treatment summary if applicable
How CMCS Coordinates TNBC Care in Shanghai
China Medical Concierge Shanghai (CMCS) is a health management company — not a hospital — that specializes in connecting international patients with Shanghai's leading specialists. For TNBC patients, our coordination includes:
- Case triage to the most appropriate medical oncologist and surgical team based on disease stage, molecular profile, and treatment history
- Medical record translation and clinical summary preparation
- Multidisciplinary tumor board submission and review coordination
- Appointment scheduling across medical oncology, breast surgery, radiation oncology, and plastic surgery
- On-site interpretation during all consultations and procedures
- Clinical trial eligibility assessment and enrollment support
- Coordination of genetic counseling and BRCA testing
- Post-treatment follow-up and surveillance coordination
- Liaison with the patient's home oncologist for continuity of care
Contact CMCS to Begin Your TNBC Consultation
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
CMCS – China Medical Concierge Shanghai connects international patients with Shanghai's leading specialists. We are a health management company, not a hospital. All clinical decisions are made by the treating physician. This guide is for informational purposes only and does not constitute medical advice.
0 Kommentare